<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antimalarials: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int334-antimalarials.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int334-antimalarials.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int334-antimalarials.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int325-promethazine.htm" title="Previous: Promethazine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int937-artemether-with-lumefantrine.htm" title="Next: Artemether with Lumefantrine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Antimalarials</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Antimalarials</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>antimalarials</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span>avoidance of </span> <span>antimalarials</span> <span>advised by manufacturer of</span> <span>histamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antimalarials</span> <span>inactivate</span> <span>oral typhoid vaccine</span> <span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span>  </p></td><td></td></tr></tbody></table><p><strong>Artemether with Lumefantrine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>amiodarone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int229-antidepressants.htm">Antidepressants</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>antidepressants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>imidazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>triazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int334-antimalarials.htm">Antimalarials</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>antimalarials</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>artemether/lumefantrine</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>disopyramide</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>flecainide</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>artemether/lumefantrine</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>indinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>macrolides</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>artemether/lumefantrine</span> <span>given with</span> <span>quinine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int193-quinolones.htm">Quinolones</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>quinolones</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises avoid concomitant use with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span>manufacturer of </span> <span>artemether/lumefantrine</span> <span>advises caution with</span> <span>tipranavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>artemether/lumefantrine</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Lumefantrine</strong> belongs to <strong>Antimalarials</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Lumefantrine interactions as for artemether with lumefantrine</p></div><p><strong>Chloroquine and Hydroxychloroquine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1012-agalsidase-alfa-and-beta.htm">Agalsidase Alfa and Beta</a></td><td><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>possibly inhibit effects of</span> <span>agalsidase alfa and beta</span> <span>(manufacturers of <span>agalsidase alfa and beta</span> advise avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>chloroquine and hydroxychloroquine</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>chloroquine and hydroxychloroquine</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>increase plasma concentration of</span> <span>ciclosporin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>chloroquine and hydroxychloroquine</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>possibly increase plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>chloroquine and hydroxychloroquine</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int14-kaolin.htm">Kaolin</a></td><td><p><span>absorption of </span> <span>chloroquine and hydroxychloroquine</span> <span>reduced by</span> <span>kaolin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1092-lanthanum.htm">Lanthanum</a></td><td><p><span>absorption of  </span> <span>chloroquine and hydroxychloroquine</span> <span>possibly reduced by</span> <span>lanthanum</span> <span>(give at least 2 hours apart)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1013-laronidase.htm">Laronidase</a></td><td><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>possibly inhibit effects of</span> <span>laronidase</span> <span>(manufacturer of <span>laronidase</span> advises avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>increased risk of convulsions when </span> <span>chloroquine and hydroxychloroquine</span> <span>given with</span> <span>mefloquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>chloroquine and hydroxychloroquine</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int647-neostigmine.htm">Neostigmine</a></td><td><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>have potential to increase symptoms of myasthenia gravis and thus diminish effect of</span> <span>neostigmine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int648-pyridostigmine.htm">Pyridostigmine</a></td><td><p><span></span> <span>chloroquine and hydroxychloroquine</span> <span>have potential to increase symptoms of myasthenia gravis and thus diminish effect of</span> <span>pyridostigmine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Hydroxychloroquine</strong> belongs to <strong>Antimalarials</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Hydroxychloroquine interactions as for chloroquine and hydroxychloroquine</p></div><p><strong>Mefloquine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>mefloquine</span> <span>antagonises anticonvulsant effect of</span> <span>antiepileptics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>increased risk of bradycardia when </span> <span>mefloquine</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>possible increased risk of bradycardia when </span> <span>mefloquine</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>increased risk of convulsions when </span> <span>mefloquine</span> <span>given with</span> <span>chloroquine and hydroxychloroquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span>possible increased risk of bradycardia when </span> <span>mefloquine</span> <span>given with</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>ivabradine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>mefloquine</span> <span>increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>mefloquine</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of convulsions when </span> <span>mefloquine</span> <span>given with</span> <span>quinine</span> <span>(but should not prevent the use of intravenous<span>quinine</span> in severe cases)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>mefloquine</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Primaquine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int610-mepacrine.htm">Mepacrine</a></td><td><p><span>plasma concentration of </span> <span>primaquine</span> <span>increased by</span> <span>mepacrine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Proguanil</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int113-magnesium-salts-oral.htm">Magnesium Salts (oral)</a></td><td><p><span>absorption of </span> <span>proguanil</span> <span>reduced by</span> <span>oral magnesium salts</span> <span>(as magnesium trisilicate)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td><p><span>increased antifolate effect when </span> <span>proguanil</span> <span>given with</span> <span>pyrimethamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span>isolated reports that </span> <span>proguanil</span> <span>may enhance anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Pyrimethamine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span></span> <span>pyrimethamine</span> <span>increases antifolate effect of</span> <span>methotrexate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1171-pemetrexed.htm">Pemetrexed</a></td><td class="cAI"><p><span></span> <span>pyrimethamine</span> <span>increases antifolate effect of</span> <span>pemetrexed</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>pyrimethamine</span> <span>antagonises anticonvulsant effect of</span> <span>phenytoin</span> <span>, also increased antifolate effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int339-proguanil.htm">Proguanil</a></td><td><p><span>increased antifolate effect when </span> <span>pyrimethamine</span> <span>given with</span> <span>proguanil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td class="cAI"><p><span>increased antifolate effect when </span> <span>pyrimethamine</span> <span>given with</span> <span>sulfonamides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td class="cAI"><p><span>increased antifolate effect when </span> <span>pyrimethamine</span> <span>given with</span> <span>trimethoprim</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span>increased antifolate effect when </span> <span>pyrimethamine</span> <span>given with</span> <span>zidovudine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Quinine</strong> belongs to <strong>Antimalarials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int555-amantadine.htm">Amantadine</a></td><td><p><span></span> <span>quinine</span> <span>possibly increases plasma concentration of</span> <span>amantadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>atazanavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>quinine</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>darunavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>quinine</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>quinine</span> <span>increases plasma concentration of</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>indinavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>increased risk of convulsions when </span> <span>quinine</span> <span>given with</span> <span>mefloquine</span> <span>(but should not prevent the use of intravenous<span>quinine</span> in severe cases)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>nelfinavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>quinine</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>quinine</span> <span>possibly enhances effects of</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quinine</span> <span>possibly increased by</span> <span>tipranavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span>plasma concentration of both drugs increased when </span> <span>quinine</span> <span>given with</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_bnf_int937-artemether-with-lumefantrine"><a href="bnf_int937-artemether-with-lumefantrine.htm" title="Artemether with Lumefantrine">Artemether with Lumefantrine</a></li><li id="_bnf_int335-chloroquine-and-hydroxychloroquine"><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm" title="Chloroquine and Hydroxychloroquine">Chloroquine and Hydroxychloroquine</a></li><li><a href="bnf_int337-mefloquine.htm" title="Mefloquine">Mefloquine</a></li><li><a href="bnf_int338-primaquine.htm" title="Primaquine">Primaquine</a></li><li><a href="bnf_int339-proguanil.htm" title="Proguanil">Proguanil</a></li><li><a href="bnf_int340-pyrimethamine.htm" title="Pyrimethamine">Pyrimethamine</a></li><li><a href="bnf_int341-quinine.htm" title="Quinine">Quinine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int325-promethazine.htm">Previous: Promethazine</a> | <a class="top" href="bnf_int334-antimalarials.htm#">Top</a> | <a accesskey="]" href="bnf_int937-artemether-with-lumefantrine.htm">Next: Artemether with Lumefantrine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>